phospholipase B domain containing 2Genealiases: P76 · PLBL2
Q-omics provides the consensus-scored PLBD2 profile across patient tissues and cancer cell-line models. PLBD2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PLBD2 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, PLBD2 RNA expression shows 19,510 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, HNSC, and THYM as cancer lineages where PLBD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLBD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLBD2 survival associations across molecular data types. PLBD2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLBD2 RNA expression–survival associations across cancer types. High PLBD2 expression shows unfavorable associations in MESO, KIRP, BLCA, LAML and UVM, but favorable associations in SCLC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PLBD2 RNA expression.
This table summarizes PLBD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PLBD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLBD2 shows higher tumor expression in HNSC, KIRP, KIRC, LIHC, STAD and LUAD. The HNSC box plot shows higher PLBD2 RNA expression in tumor versus normal tissue (log2 FC = +2.216, t-test p < 0.001).
This table shows molecular features associated with PLBD2 in patient tissues and cancer cell lines. In patient samples, PLBD2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLBD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
